Active substance | olipudase alfa |
Holder | Sanofi |
Status | Running |
Indication | acid sphingomyelinase deficiency for patients who have participated and exit the clinical studies DFI-12712-ASCEND or LTS-13632 |
Public documents | Approbation |
Approbation amendment | |
Information for the patient | |
Informed consent | |
Last update | 10/08/2022 |